Watching Bionano Genomics Inc. (BNGO) For Insider Activity

Bionano Genomics Inc. (NASDAQ:BNGO) finished Wednesday with a subtraction of $0.0 to close at $5.36, a downside of 0.00 percent. An average of 6,677,180 shares of common stock have been traded in the last five days. There was a gain of $0.40 in the past week. The last 20 days have seen an average of 8,074,500 shares traded, while the 50-day average volume stands at 7,867,422.

BNGO stock has increased by 3.08% in the last month. The company shares reached their 1-month lowest point of $4.92 on 10/07/21. With the stock rallying to its 52-week high on 02/16/21, shares of the company touched a low of $0.47 and a high of $15.69 in 52 weeks. In spite of this, the price is down -65.84% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

Bionano Genomics Inc. (BNGO) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 32.30 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 114.01, the price-to-book (PB) ratio at 4.32.

The quick ratio of Bionano Genomics Inc. for the three months ended June 29 was 31.40, and the current ratio was 31.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 33.30% against a 5-year average of 35.4%. Bionano Genomics Inc.’s EBITDA margin for the year ending June 29 is -418.40%. Its gross profit as reported stood at $2.77 million compared to revenue of $8.5 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Bionano Genomics Inc.’s return on assets was -24.30%, compared to -124.0% over the last five years. For the broader industry, ROE averaged -2.89 over the past year.

Earnings Surprise

The analyst consensus anticipated Bionano Genomics Inc.’s latest quarter earnings to come in at -$0.04 per share, but it turned out to be -$0.07, a -75.00% surprise. For the quarter, EBITDA amounted to -$15.96 million. At the end of the quarter ending June 29, Bionano Genomics Inc.’s stock balance sheet showed total liabilities of 10.94 million. Shareholders own equity worth $279.14 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Bionano Genomics Inc. (BNGO) price momentum. RSI 9-day as of the close on 13 October was 53.27%, suggesting the stock is Neutral, with historical volatility in this time frame at 57.03%.

As of today, BNGO’s price is $5.23 +8.06% or $0.40 from its 5-day moving average. BNGO is currently trading +1.52% higher than its 20-day SMA and -2.90% lower than its 100-day SMA. However, the stock’s current price level is -9.46% below the SMA50 and +506.20% above the SMA200.

The stochastic %K and %D were 47.56% and 38.67%, respectively, and the average true range (ATR) was 0.27. With the 14-day stochastic at 58.67% and the average true range at 0.28, the RSI (14) stands at 49.81%. The stock has reached 0.11 on the 9-day MACD Oscillator while the 14-day reading was at 0.01.

Analyst Ratings

BTIG Research launched coverage on Bionano Genomics Inc. (NASDAQ: BNGO) in its analyst report released on June 16, 2021. The firm assigned the stock a a Buy rating.The consensus rating for Bionano Genomics Inc. (BNGO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BNGO, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.

What is BNGO’s price target for the next 12 months?

Analysts predict a range of price targets between $10.00 and $14.00, with a median target of $12.00. Taking a look at these predictions, the average price target given by analysts for Bionano Genomics Inc. (BNGO) stock is $12.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam